Clinical Validation of the TruSight Oncology 500 Assay for the Detection and Reporting of Pan- Cancer Biomarkers

Hussam Al-Kateb,Shannon M. Knight, Gopinath Sivasankaran,Jesse S. Voss,Beth A. Pitel,Joseph H. Blommel,Calvin R. Jerde, Kandeleria M. Rumilla, Jodi L. Lee, Nate R. Mattson, Kim P. Lauer, Eric A Zimmerman Zuckerman, Chris D. Hofich,Dragana Milosevic, Joe Thompson, Lori S. Tillmans, Tony T. Stai,Surendra Dasari, Amber L. Pryzbylski, Lisa G. Mullineaux

The Journal of Molecular Diagnostics（2025）

Cited 0|Views1

Key words

Next-Generation-Sequencing,Solid tumors,TruSight Oncology 500 (TSO500) High-Throughput assay validation,Tumor genomic profiling,Tumor mutation burden (TMB),Microsatellite instability (MSI),Single nucleotide variants and short deletions/insertions,Gene amplifications,Gene fusion,Splice variants

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined